Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2020 Oct 22;29(12):2486–2494. doi: 10.1158/1055-9965.EPI-20-0223

Table 1:

Validated BE early detection markers

Biomarker Method Study Design AUC Sensitivity Specificity Ref.
TFF3 IHC (cytosponge) BEST-2: Case-control (N=1110) 80% 92% 42
mVIM and mCCNA1 bsNSG (Esocheck device) Case-control Validation cohort (N=86) 90% 92% 36
mB3GAT2 methyLight PCR (endoscopic brushings) Case-control Validation cohort (N=66) 0.95 80% 86% 37
mZNF793 methyLight PCR (endoscopic brushings) Case-control Validation cohort (N=66) 0.96 80% 93% 37
mTFPI2 methyLight PCR (cytosponge) Case-control Validation cohort (N=278) 0.88 (0.84–0.91 82% 96% 41
mTWIST1 methyLight PCR (cytosponge) Case-control validation cohort (N=278) 81% (0.77–0.86) 70% 93% 41

IHC=immunohistochemistry, bsNSG=bisulfite next generation sequencing

Table 1 below summarizes BE biomarkers that have been evaluated in clinical cohorts.